Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT
To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2016, Vol.51 (1), p.43-50 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 43 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 51 |
| creator | Nishiwaki, S Imai, K Mizuta, S Kanamori, H Ohashi, K Fukuda, T Onishi, Y Takahashi, S Uchida, N Eto, T Nakamae, H Yujiri, T Mori, S Nagamura-Inoue, T Suzuki, R Atsuta, Y Tanaka, J |
| description | To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(−)) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD(−) was significantly better than that in patients transplanted in MRD(+) (MRD(−): 67% vs MRD(+): 55% at 4 years;
P
=0.001). MRD(−) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD(−) was significantly lower than that in patients transplanted in MRD(+) (MRD(−): 19% vs MRD(+): 29% at 4 years;
P
=0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (
P |
| doi_str_mv | 10.1038/bmt.2015.217 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1765977083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A440058548</galeid><sourcerecordid>A440058548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5677-4a578eaf1060ab90060782c3b4648f2cb1dfe817a0d8dde46aa56b2cc8fbcf113</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhxhlZQkJIkMWOP-L0ttpCu7AIBIs4Wo5jb1I5cbCdQw_97zjaAi2qQD6MPPPMjN6ZybKnCC4RxPxN3cdlARFdFqi8ly0QKVlOMaP3swUsGM8xZtVR9iiECwgRIZA-zI4KhnnFMV5kV5t-lCoCZ8DHL6dADg3YfdgANwBprdvrQXcKtLqX0Y2u0zH9lLYWRC-HMFo5RBm7RBvnwef21Wq7PQEShDg1l8B414PYaiCbyUaQYuD72dxp9r3_er7ePc4eGGmDfnJtj7Nv797u1uf59tPZZr3a5oqyssyJpCXX0iDIoKwrmEzJC4Vrwgg3hapRYzRHpYQNbxpNmJSU1YVS3NTKIISPs5eHuqN3PyYdoui7MOuQg3ZTEKhktCpLmEbyf5QSWhSoqhL6_C_0wk1-SEJEwUhaB0GY_YtKtTDBqR7-Q-2l1aIbjEsTVnNrsUpLg5RTwhO1vINKr9F9p9ygTZf8txJe3EhotbSxDc5O887CbfD1AVTeheC1EaPveukvBYJivjOR7kzMdyaSsIQ_uxY11b1ufsO_DisB-QEIKTTstb-h-q6CPwErdNa9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753435453</pqid></control><display><type>article</type><title>Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><creator>Nishiwaki, S ; Imai, K ; Mizuta, S ; Kanamori, H ; Ohashi, K ; Fukuda, T ; Onishi, Y ; Takahashi, S ; Uchida, N ; Eto, T ; Nakamae, H ; Yujiri, T ; Mori, S ; Nagamura-Inoue, T ; Suzuki, R ; Atsuta, Y ; Tanaka, J</creator><creatorcontrib>Nishiwaki, S ; Imai, K ; Mizuta, S ; Kanamori, H ; Ohashi, K ; Fukuda, T ; Onishi, Y ; Takahashi, S ; Uchida, N ; Eto, T ; Nakamae, H ; Yujiri, T ; Mori, S ; Nagamura-Inoue, T ; Suzuki, R ; Atsuta, Y ; Tanaka, J ; for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><description>To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(−)) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD(−) was significantly better than that in patients transplanted in MRD(+) (MRD(−): 67% vs MRD(+): 55% at 4 years;
P
=0.001). MRD(−) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD(−) was significantly lower than that in patients transplanted in MRD(+) (MRD(−): 19% vs MRD(+): 29% at 4 years;
P
=0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (
P
<0.0001). MRD status at allo-HCT is one of the most important predictive factors for Ph+ALL patients transplanted in CR1.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2015.217</identifier><identifier>PMID: 26389833</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1990/283/2125 ; Adolescent ; Adult ; Aged ; Allografts ; Analysis ; Attention deficit hyperactivity disorder ; Bone marrow ; Care and treatment ; Cell Biology ; Complications and side effects ; Development and progression ; Enzyme inhibitors ; Female ; Health aspects ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Internal Medicine ; Japan - epidemiology ; Kinases ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Minimal residual disease ; Multivariate analysis ; Neoplasm, Residual ; original-article ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Protein Kinase Inhibitors - administration & dosage ; Protein-tyrosine kinase ; Public Health ; Registries ; Risk analysis ; Risk factors ; Stem cell transplantation ; Stem Cells ; Transplantation ; Transplants & implants ; Tyrosine</subject><ispartof>Bone marrow transplantation (Basingstoke), 2016, Vol.51 (1), p.43-50</ispartof><rights>Macmillan Publishers Limited 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2016</rights><rights>Macmillan Publishers Limited 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5677-4a578eaf1060ab90060782c3b4648f2cb1dfe817a0d8dde46aa56b2cc8fbcf113</citedby><cites>FETCH-LOGICAL-c5677-4a578eaf1060ab90060782c3b4648f2cb1dfe817a0d8dde46aa56b2cc8fbcf113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2015.217$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2015.217$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26389833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishiwaki, S</creatorcontrib><creatorcontrib>Imai, K</creatorcontrib><creatorcontrib>Mizuta, S</creatorcontrib><creatorcontrib>Kanamori, H</creatorcontrib><creatorcontrib>Ohashi, K</creatorcontrib><creatorcontrib>Fukuda, T</creatorcontrib><creatorcontrib>Onishi, Y</creatorcontrib><creatorcontrib>Takahashi, S</creatorcontrib><creatorcontrib>Uchida, N</creatorcontrib><creatorcontrib>Eto, T</creatorcontrib><creatorcontrib>Nakamae, H</creatorcontrib><creatorcontrib>Yujiri, T</creatorcontrib><creatorcontrib>Mori, S</creatorcontrib><creatorcontrib>Nagamura-Inoue, T</creatorcontrib><creatorcontrib>Suzuki, R</creatorcontrib><creatorcontrib>Atsuta, Y</creatorcontrib><creatorcontrib>Tanaka, J</creatorcontrib><creatorcontrib>for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><title>Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(−)) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD(−) was significantly better than that in patients transplanted in MRD(+) (MRD(−): 67% vs MRD(+): 55% at 4 years;
P
=0.001). MRD(−) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD(−) was significantly lower than that in patients transplanted in MRD(+) (MRD(−): 19% vs MRD(+): 29% at 4 years;
P
=0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (
P
<0.0001). MRD status at allo-HCT is one of the most important predictive factors for Ph+ALL patients transplanted in CR1.</description><subject>631/67/1990/283/2125</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Allografts</subject><subject>Analysis</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Japan - epidemiology</subject><subject>Kinases</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Minimal residual disease</subject><subject>Multivariate analysis</subject><subject>Neoplasm, Residual</subject><subject>original-article</subject><subject>Philadelphia Chromosome</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein-tyrosine kinase</subject><subject>Public Health</subject><subject>Registries</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Tyrosine</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkk1v1DAQhiMEokvhxhlZQkJIkMWOP-L0ttpCu7AIBIs4Wo5jb1I5cbCdQw_97zjaAi2qQD6MPPPMjN6ZybKnCC4RxPxN3cdlARFdFqi8ly0QKVlOMaP3swUsGM8xZtVR9iiECwgRIZA-zI4KhnnFMV5kV5t-lCoCZ8DHL6dADg3YfdgANwBprdvrQXcKtLqX0Y2u0zH9lLYWRC-HMFo5RBm7RBvnwef21Wq7PQEShDg1l8B414PYaiCbyUaQYuD72dxp9r3_er7ePc4eGGmDfnJtj7Nv797u1uf59tPZZr3a5oqyssyJpCXX0iDIoKwrmEzJC4Vrwgg3hapRYzRHpYQNbxpNmJSU1YVS3NTKIISPs5eHuqN3PyYdoui7MOuQg3ZTEKhktCpLmEbyf5QSWhSoqhL6_C_0wk1-SEJEwUhaB0GY_YtKtTDBqR7-Q-2l1aIbjEsTVnNrsUpLg5RTwhO1vINKr9F9p9ygTZf8txJe3EhotbSxDc5O887CbfD1AVTeheC1EaPveukvBYJivjOR7kzMdyaSsIQ_uxY11b1ufsO_DisB-QEIKTTstb-h-q6CPwErdNa9</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Nishiwaki, S</creator><creator>Imai, K</creator><creator>Mizuta, S</creator><creator>Kanamori, H</creator><creator>Ohashi, K</creator><creator>Fukuda, T</creator><creator>Onishi, Y</creator><creator>Takahashi, S</creator><creator>Uchida, N</creator><creator>Eto, T</creator><creator>Nakamae, H</creator><creator>Yujiri, T</creator><creator>Mori, S</creator><creator>Nagamura-Inoue, T</creator><creator>Suzuki, R</creator><creator>Atsuta, Y</creator><creator>Tanaka, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2016</creationdate><title>Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT</title><author>Nishiwaki, S ; Imai, K ; Mizuta, S ; Kanamori, H ; Ohashi, K ; Fukuda, T ; Onishi, Y ; Takahashi, S ; Uchida, N ; Eto, T ; Nakamae, H ; Yujiri, T ; Mori, S ; Nagamura-Inoue, T ; Suzuki, R ; Atsuta, Y ; Tanaka, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5677-4a578eaf1060ab90060782c3b4648f2cb1dfe817a0d8dde46aa56b2cc8fbcf113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/67/1990/283/2125</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Allografts</topic><topic>Analysis</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Japan - epidemiology</topic><topic>Kinases</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Minimal residual disease</topic><topic>Multivariate analysis</topic><topic>Neoplasm, Residual</topic><topic>original-article</topic><topic>Philadelphia Chromosome</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein-tyrosine kinase</topic><topic>Public Health</topic><topic>Registries</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishiwaki, S</creatorcontrib><creatorcontrib>Imai, K</creatorcontrib><creatorcontrib>Mizuta, S</creatorcontrib><creatorcontrib>Kanamori, H</creatorcontrib><creatorcontrib>Ohashi, K</creatorcontrib><creatorcontrib>Fukuda, T</creatorcontrib><creatorcontrib>Onishi, Y</creatorcontrib><creatorcontrib>Takahashi, S</creatorcontrib><creatorcontrib>Uchida, N</creatorcontrib><creatorcontrib>Eto, T</creatorcontrib><creatorcontrib>Nakamae, H</creatorcontrib><creatorcontrib>Yujiri, T</creatorcontrib><creatorcontrib>Mori, S</creatorcontrib><creatorcontrib>Nagamura-Inoue, T</creatorcontrib><creatorcontrib>Suzuki, R</creatorcontrib><creatorcontrib>Atsuta, Y</creatorcontrib><creatorcontrib>Tanaka, J</creatorcontrib><creatorcontrib>for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishiwaki, S</au><au>Imai, K</au><au>Mizuta, S</au><au>Kanamori, H</au><au>Ohashi, K</au><au>Fukuda, T</au><au>Onishi, Y</au><au>Takahashi, S</au><au>Uchida, N</au><au>Eto, T</au><au>Nakamae, H</au><au>Yujiri, T</au><au>Mori, S</au><au>Nagamura-Inoue, T</au><au>Suzuki, R</au><au>Atsuta, Y</au><au>Tanaka, J</au><aucorp>for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2016</date><risdate>2016</risdate><volume>51</volume><issue>1</issue><spage>43</spage><epage>50</epage><pages>43-50</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(−)) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD(−) was significantly better than that in patients transplanted in MRD(+) (MRD(−): 67% vs MRD(+): 55% at 4 years;
P
=0.001). MRD(−) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD(−) was significantly lower than that in patients transplanted in MRD(+) (MRD(−): 19% vs MRD(+): 29% at 4 years;
P
=0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (
P
<0.0001). MRD status at allo-HCT is one of the most important predictive factors for Ph+ALL patients transplanted in CR1.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26389833</pmid><doi>10.1038/bmt.2015.217</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2016, Vol.51 (1), p.43-50 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1765977083 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; Nature Journals Online |
| subjects | 631/67/1990/283/2125 Adolescent Adult Aged Allografts Analysis Attention deficit hyperactivity disorder Bone marrow Care and treatment Cell Biology Complications and side effects Development and progression Enzyme inhibitors Female Health aspects Hematology Hematopoietic Stem Cell Transplantation Humans Internal Medicine Japan - epidemiology Kinases Male Medicine Medicine & Public Health Middle Aged Minimal residual disease Multivariate analysis Neoplasm, Residual original-article Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Protein Kinase Inhibitors - administration & dosage Protein-tyrosine kinase Public Health Registries Risk analysis Risk factors Stem cell transplantation Stem Cells Transplantation Transplants & implants Tyrosine |
| title | Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A30%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20MRD%20and%20TKI%20on%20allogeneic%20hematopoietic%20cell%20transplantation%20for%20Ph+ALL:%20a%20study%20from%20the%20adult%20ALL%20WG%20of%20the%20JSHCT&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Nishiwaki,%20S&rft.aucorp=for%20the%20Adult%20Acute%20Lymphoblastic%20Leukemia%20Working%20Group%20of%20the%20Japan%20Society%20for%20Hematopoietic%20Cell%20Transplantation&rft.date=2016&rft.volume=51&rft.issue=1&rft.spage=43&rft.epage=50&rft.pages=43-50&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2015.217&rft_dat=%3Cgale_proqu%3EA440058548%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1753435453&rft_id=info:pmid/26389833&rft_galeid=A440058548&rfr_iscdi=true |